Selective Serotonin 2a/2c Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases

Abstract

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.


Claims
IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Dec 31, 2013
  • Application: Jan 25, 2013
    US US 201313750778 A
  • Priority: Jan 25, 2013
    US US 201313750778 A
  • Priority: Jun 29, 2012
    US US 201213539011 A
  • Priority: Jun 27, 2011
    US US 201113169893 A
  • Priority: Apr 13, 2010
    US US 75966210 A
  • Priority: May 3, 2006
    US US 41652706 A
  • Priority: Jan 15, 2004
    US US 75956104 A
  • Priority: Jun 17, 2003
    US US 47934603 P
  • Priority: Jan 16, 2003
    US US 44140603 P

Download Citation


Sign in to the Lens

Feedback